Patent intelligence · US
US 11008564
Processing engineered FMDV P1 polypeptide using an alternative TEV protease
Processing engineered FMDV P1 polypeptide using an alternative TEV protease
Patent details — US 11008564
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2021
- Expiration
- May 13, 2041
- Applicant
- The Government of the United States of America, as represented by the Secretary of Homeland Security
- Claims
- 20
- CPC classes
- A61K, A61K2039/523, A61K2039/5254, A61K2039/5258
Quick answer
US 11008564 (Processing engineered FMDV P1 polypeptide using an alternative TEV protease) is held by The Government of the United States of America, as represented by the Secretary of Homeland Security. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Government of the United States of America, as represented by the Secretary of Homeland Security
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/523, A61K2039/5254, A61K2039/5258, A61K39/12, A61P
More from The Government of the United States of America, as represented by the Secretary of Homeland Security
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 11008564?
US 11008564 (Processing engineered FMDV P1 polypeptide using an alternative TEV protease) is held by The Government of the United States of America, as represented by the Secretary of Homeland Security. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11008564?
The Government of the United States of America, as represented by the Secretary of Homeland Security is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 11008564 expire?
Our index shows an expiration date of May 13, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.